Scancell: Funding, Investors & Team (Sep 2026)
Scancell is creating therapeutic vaccines for the treatment of cancer and infectious diseases using its ImmunoBody® and Moditope™ technology platforms. The company's initial cancer vaccine, SCIB1, is currently in Phase 1/2 clinical trials for melanoma treatment. Initial findings from Part 1 of the study, released in December 2012, demonstrated that SCIB1 generated an immune response that could potentially have clinical benefits for patients with malignant melanoma.
Scancell has raised $13.5M across 1 funding round on record, the most recent an undisclosed round of $13.5M announced in Dec 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Scancell Company Profile and Key Stats
Latest funding round on record: Dec 2023.
Scancell Funding Rounds
Scancell Founders and Leadership Team
Contact details for the Scancell team: 1 of 1 has an email address on file.
Start 14-day free trial →Scancell Funding Compared to Other Biotechnology Startups
Scancell's latest round of $13.5M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Scancell in Biotechnology and Nottingham
Companies Similar to Scancell
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
IMU is a discovery engine mapping the immune system to advance precision medicine.
Mykor is a climate tech start-up. It decarbonizes the construction industry by manufacturing carbon-negative…
Neurovalens provides cutting-edge solutions in the realms of neuroscience, bioscience, and neurophysiology.…
Voxmind's biometric confirmation and authentication platform that provides voice based biometrics that helps…
Five is a biometric payment services company that offers thumb recognition technology for safe transactions.
Scancell Funding FAQs
What does Scancell do?
Scancell is creating therapeutic vaccines for the treatment of cancer and infectious diseases using its ImmunoBody® and Moditope™ technology platforms. The company's initial cancer vaccine, SCIB1, is currently in Phase 1/2 clinical trials for melanoma treatment. Initial findings from Part 1 of the study, released in December 2012, demonstrated that SCIB1 generated an immune response that could potentially have clinical benefits for patients with malignant melanoma.
How much funding has Scancell raised?
Scancell has raised $13.5M across 1 round on record. The most recent is an undisclosed round of $13.5M announced in Dec 2023.
When did Scancell last raise funding?
Scancell's most recent funding round on record is an undisclosed round of $13.5M, announced in Dec 2023.
Who is the CEO of Scancell?
Lindy Durrant is listed as CEO at Scancell.
Where is Scancell headquartered?
Scancell is based in Nottingham, United Kingdom.
How many employees does Scancell have?
Scancell is in the 51-100 employee band.
How does Scancell's funding compare to other Biotechnology startups?
Scancell's latest round of $13.5M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Scancell Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Scancell is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.